European Innovation Council

neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam.

Limula provides a unique platform technology enabling scale out of cell therapy production. Our patent-granted solution is combining a bioreactor and a centrifuge into one device, for the first time. Our product is composed of hardware, software and consumables, allowing healthcare providers to safely manufacture CGT in a decentralised manner. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Scipio Bioscience, a Paris-based biotechnology company, provides a novel sample preparation solutionfor single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics.

Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested today, by introducing the first “Organism-on-Chip” technology.

Xsensio is an innovation-driven digital health company dedicated to solving one of the biggest challenges in healthcare: the lack of real-time, continuous monitoring of relevant health parameters. We take the industry from a static approach today, to a dynamic one. To achieve this vision, Xsensio is building the breakthrough Lab-on-Skin© wearable: a modular miniaturized sensing platform that will offer unique health insight through the continuous and real-time analysis of proteins and hormones at the surface of the skin during critical health events, to improve standard of care in a simple and minimally-invasive way.

Palobiofarma is a Spanish Biotech company located in Barcelona’s Science Park. Our mission is to discover and develop new drugs based on the modulation of the adenosine receptors. Our vision is to be the first european adenosine drug discovery company

Palobiofarma is a Spanish Biotech company located in Barcelona’s Science Park. Our mission is to discover and develop new drugs based on the modulation of the adenosine receptors. Our vision is to be the first european adenosine drug discovery company

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Ilya Pharma is a company that plans to solve the problem through a technique that makes the wounds heal faster. Ilya Pharma develops next-generation biological drugs for treating wounds in skin and mucosa. The company's business is to genetically rebuild lactic acid bacteria, such as those found in yogurt, so that they produce a bodily substance that speeds up the skin's healing. Ilya Pharma, founded 2016, is a spin-out pharmaceutical company and the innovation stems from many years of scientific reasearch at Uppsala University and the Swedish University of Agriculture.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Xsensio is an innovation-driven digital health company dedicated to solving one of the biggest challenges in healthcare: the lack of real-time, continuous monitoring of relevant health parameters. We take the industry from a static approach today, to a dynamic one. To achieve this vision, Xsensio is building the breakthrough Lab-on-Skin© wearable: a modular miniaturized sensing platform that will offer unique health insight through the continuous and real-time analysis of proteins and hormones at the surface of the skin during critical health events, to improve standard of care in a simple and minimally-invasive way.

Xsensio is an innovation-driven digital health company dedicated to solving one of the biggest challenges in healthcare: the lack of real-time, continuous monitoring of relevant health parameters. We take the industry from a static approach today, to a dynamic one. To achieve this vision, Xsensio is building the breakthrough Lab-on-Skin© wearable: a modular miniaturized sensing platform that will offer unique health insight through the continuous and real-time analysis of proteins and hormones at the surface of the skin during critical health events, to improve standard of care in a simple and minimally-invasive way.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

S-Biomedic brings novel therapeutic solutions to the skin microbiome.The skin microbiome - a habitat of billions of beneficial and harmful bacteria - contributes to healthy skin. An imbalance of these bacteria can lead to a variety of skin conditions including acne, eczema, rosacea and ageing. S-Biomedic uses a targeted modulation-based technology to modify the skin microbiome. This technology can be applied in both the dermatology and cosmetic industries. They design their products using the latest advances in microbiology and dermatology. Using their technology, beneficial bacteria are selected and combined to generate products that accelerate the rebalancing of a disease microbiome. In this way, they are able to restore a healthy state back to your skin.